{"id":7965,"date":"2004-04-12T14:12:00","date_gmt":"2004-04-12T14:12:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=7965"},"modified":"2022-04-12T14:25:27","modified_gmt":"2022-04-12T14:25:27","slug":"adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/","title":{"rendered":"Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn’s disease"},"content":{"rendered":"
\n

Takeshi Kusaka<\/a>\u00a01<\/a><\/sup>,\u00a0Ken Fukunaga<\/a>,\u00a0Kunio Ohnishi<\/a>,\u00a0Tadashi Kosaka<\/a>,\u00a0Toshihiko Tomita<\/a>,\u00a0Yoko Yokoyama<\/a>,\u00a0Koji Sawada<\/a>,\u00a0Yoshihiro Fukuda<\/a>,\u00a0Hiroto Miwa<\/a>,\u00a0Takayuki Matsumoto<\/a> J Clin Apher. <\/a>2004;19(4):168-73.\u00a0doi: 10.1002\/jca.20023. <\/p>\n<\/div>\n\n

\n

Six patients with active Crohn’s disease (CD) unresponsive to conventional medications (CM) were treated with Monocyte-granulocytapheresis (M-GCAP). CD patients who scored 200-400 points in Crohn’s disease activity index (CDAI) in spite of receiving CM, including enteral nutrition, for at least 2 weeks were enrolled in our double series trial. Each series had 5 weekly M-GCAP and 2 follow-up weeks, and each M-GCAP treated 1,800 ml of patient’s peripheral blood. After the 1st series, patients who decreased more than 50 points on the CDAI were deemed responders and enrolled in the second series. Patients with a CDAI score less than 150 points were considered in remission. The patients’ quality of life was evaluated using an index (IBDQ) before and after the 1st series. The CDAI was significantly decreased comparing before and after the 1st series (258.2 +\/- 36.2 vs. 166.5 +\/- 16.6; P < 0.02). 50% of patients (3\/6) responded to the therapy, and one case (16.7%) could be induced to remission. Significant removal was revealed only for white blood cells (25.6 +\/- 16.9%; P < 0.05), especially granulocytes (29.5 +\/- 22.5%; P < 0.05). A statistically significant improvement of IBDQ was revealed in the responders’ group (162.3 +\/- 17.2 vs. 189.3 +\/- 11.5; P < 0.03). M-GCAP could be an effective adjunctive therapy for active CD patients unresponsive to CM allowing them to maintain a high QOL. However, it might be difficult to improve patients who could not be induced to remission after the 1st series by applying another series.<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/15597346\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Takeshi Kusaka\u00a01,\u00a0Ken Fukunaga,\u00a0Kunio Ohnishi,\u00a0Tadashi Kosaka,\u00a0Toshihiko Tomita,\u00a0Yoko Yokoyama,\u00a0Koji Sawada,\u00a0Yoshihiro Fukuda,\u00a0Hiroto Miwa,\u00a0Takayuki Matsumoto J Clin Apher. 2004;19(4):168-73.\u00a0doi: 10.1002\/jca.20023. Six patients with active Crohn’s disease (CD) unresponsive to conventional medications (CM) were treated with Monocyte-granulocytapheresis (M-GCAP). CD patients who scored 200-400 points in Crohn’s disease activity index (CDAI) in spite of receiving CM, including enteral nutrition, for at […]<\/p>\n","protected":false},"template":"","scientific_tags":[147,588,159,424,181,75],"class_list":["post-7965","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission","scientific_tags-clinical-response","scientific_tags-crohns-disease","scientific_tags-gma","scientific_tags-gmas-responders","scientific_tags-qol"],"acf":[],"yoast_head":"\nAdsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Takeshi Kusaka\u00a01,\u00a0Ken Fukunaga,\u00a0Kunio Ohnishi,\u00a0Tadashi Kosaka,\u00a0Toshihiko Tomita,\u00a0Yoko Yokoyama,\u00a0Koji Sawada,\u00a0Yoshihiro Fukuda,\u00a0Hiroto Miwa,\u00a0Takayuki Matsumoto J Clin Apher. 2004;19(4):168-73.\u00a0doi: 10.1002\/jca.20023. Six patients with active Crohn’s disease (CD) unresponsive to conventional medications (CM) were treated with Monocyte-granulocytapheresis (M-GCAP). CD patients who scored 200-400 points in Crohn’s disease activity index (CDAI) in spite of receiving CM, including enteral nutrition, for at […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-12T14:25:27+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/\",\"name\":\"Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2004-04-12T14:12:00+00:00\",\"dateModified\":\"2022-04-12T14:25:27+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/","og_locale":"es_ES","og_type":"article","og_title":"Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease - Adacyte","og_description":"Takeshi Kusaka\u00a01,\u00a0Ken Fukunaga,\u00a0Kunio Ohnishi,\u00a0Tadashi Kosaka,\u00a0Toshihiko Tomita,\u00a0Yoko Yokoyama,\u00a0Koji Sawada,\u00a0Yoshihiro Fukuda,\u00a0Hiroto Miwa,\u00a0Takayuki Matsumoto J Clin Apher. 2004;19(4):168-73.\u00a0doi: 10.1002\/jca.20023. Six patients with active Crohn’s disease (CD) unresponsive to conventional medications (CM) were treated with Monocyte-granulocytapheresis (M-GCAP). CD patients who scored 200-400 points in Crohn’s disease activity index (CDAI) in spite of receiving CM, including enteral nutrition, for at […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/","og_site_name":"Adacyte","article_modified_time":"2022-04-12T14:25:27+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/","name":"Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2004-04-12T14:12:00+00:00","dateModified":"2022-04-12T14:25:27+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/adsorptive-monocyte-granulocytapheresis-m-gcap-for-refractory-crohns-disease-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/7965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=7965"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=7965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}